-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下：鑑於業績指引下調，我們將目標股價從54美元下調至36美元，並將2026年每股收益預期從2.53美元下調至2.45美元，2027年每股收益預期從2.74美元下調至2.64美元。目標股價對應的2026年本益比為14.7倍，低於其20-22倍的歷史平均水平，這反映了其主要成長動力QuantiFERON面臨的不利因素。 Qiagen公司2026年第一季初步淨銷售額年減1%，低於公司先前至少1%的成長預期，主要原因是QuantiFERON（年減5%）因美國和中東地區移民檢測需求下降而受到拖累。鑑於年初業績成長緩慢，凱傑公司將2026年銷售額成長預期從至少5%下調至1%-2%（固定匯率），並將調整後每股盈餘預期從2.50美元下調至至少2.43美元（固定匯率）。我們認為銷售額未達預期以及業績展望下調令人失望。我們仍然認為QuantiFERON是長期成長的主要貢獻者，因此密切注意其他患者檢測項目的進展仍然至關重要。完整的2026年第一季業績將於2026年5月6日公佈。
Related Articles
Asia
Atlas Arteria Says IFM Global's Takeover Offer Will Not Open Before May 11
Atlas Arteria (ASX:ALX) said an unsolicited takeover offer from IFM Global Infrastructure Fund will not open before May 11 at the earliest, and once it does, it will remain open for at least a month, according to a Friday filing with the Australian bourse.IFM owns about 35% of the issued shares of Atlas Arteria and has proposed to acquire the remaining interest at AU$4.75 per share in cash. The price may increase to AU$5.10 per share if IFM obtains at least a 45% interest before the offer closes.In a letter to its shareholders, Atlas Arteria warned that the proposal is subject to many conditions that might not be satisfied. It also cautioned that shareholders would receive the lower price if IFM's relevant interest threshold is not achieved prior to closing.Atlas Arteria has created an independent board committee to evaluate the proposal and will provide a recommendation to shareholders in due course, it said.
$ASX:ALX
US Markets
Wuliangye Yibin's First-Quarter 2026 Profit Nearly Tops Full-Year 2025 Figure
Wuliangye Yibin's (SHE:000858) first-quarter attributable profit surged 83% from the year-ago period on higher revenue despite surging sales costs.The baijiu distillery logged an attributable profit of 8.06 billion yuan during the three months through March 31, higher than 4.42 billion yuan recorded in the year-ago period, according to an after-hours filing on Thursday.The company also attributed the higher profit to a lower base in the year-ago period.First-quarter profit nearly topped the profit recorded for the whole of 2025 at 8.95 billion yuan, down 72% from 31.9 billion yuan in the year-ago period.Singapore-based investment intelligence platform Smartkarma estimated a net profit of 11.16 billion yuan.Q1 earnings per share jumped 83% to 2.0772 yuan from 1.1378 yuan.Wuliangye Yibin's revenue grew 34% to 22.8 billion yuan from 17.1 billion yuan in the prior-year period.Total operating costs jumped 11% to 12.2 billion yuan from nearly 11 billion yuan a year earlier, the baijiu manufacturer said in its filing.Sales costs surged 145% to 3.67 billion yuan from 1.49 billion yuan.The jump could mean Wuliangye is either actively increasing channel development investment and brand promotion or subsidizing dealers facing pricing pressures, Futu said in its digital platform, Futubull.Net cash flow from operating activities turned to a negative 2.54 billion yuan from positive inflows of 15.8 billion yuan in the year-ago period.A high volume of collected bills due to market changes caused the negative cash flow, Futu said, citing Wuliangye.Cash and cash equivalents stayed at 1.3 times higher than the annual revenue, Futu said.Meanwhile, the wine maker plans to repurchase between 8 billion yuan and 10 billion yuan of shares for up to 153.59 yuan apiece, according to a separate disclosure.
$SHE:000858
Asia
SJ Semiconductor Q1 Profit Up 52%
SJ Semiconductor (SHA:688820) posted first-quarter attributable net profit of 191.3 million yuan, up 52% from 126.3 million yuan the previous year.Earnings per share rose to 0.12 yuan from 0.08 yuan, according to a Thursday filing with the Shanghai bourse.The semiconductor wafer manufacturer's operating revenue climbed 13% year over year to 1.70 billion yuan from 1.50 billion yuan.
$SHA:688820